Clinical Trials on Establish Hematology Reference Intervals

Total 12 results

The Hospital for Sick Children
MINDRAY

Completed

Mindray Pediatric Hematology Reference Intervals Study

Establish Hematology Reference Intervals

Canada
Qilu Hospital of Shandong University
The First Affiliated Hospital with Nanjing Medical University; First People... and other collaborators

Recruiting

Determination of MCG Reference Intervals in Healthy Individuals

MCG Reference Intervals Determination for Healthy Adults

China
Dr Konstantinos Gerasimidis

Completed

Development of an Optimal Micronutrient Reference Range for Adults (OMIS)

Micronutrients Reference Interval | Micronutrients Normal Range

United Kingdom
Universitaire Ziekenhuizen KU Leuven

Completed

Determination of Voriconazole Levels in Saliva - Validation in Specific Subsets of Patients

Pediatrics | Hematology | Internal Medicine | Pneumology

Belgium
Institut Rafael

Active, not recruiting

Patient Preference Between a Prefilled Syringe or a Prefilled Pen Device for Administration of Pegfilgrastim (PELGRAZ)

Patient Satisfaction | Patient Preference | Febrile Neutropenia, Drug-Induced

France
iOMEDICO AG

Active, not recruiting

Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv) (MYLENE)

Multiple Myeloma | Patient Satisfaction | Personal Satisfaction | Newly Diagnosed | Transplant Ineligible | Patient Preference

Germany
Lille Catholic University

Completed

Transferrin Saturation Coefficient and Ferritinemia in Diagnosis of Iron Deficiency (CarenceMartial)

Iron-deficiency | Internal Medicine | Transferrin | Ferritinemia

France
Otsuka Australia Pharmaceutical Pty Ltd

Recruiting

A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia (PREFER-HMA)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic | Patient Preference

New Zealand, Australia
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation

Taiwan, Poland, Serbia, United States, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Portugal, Romania, Spain, Sweden, United Kingdom
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)

United States, Canada, Germany, Italy, Spain, United Kingdom, France
Mayo Clinic

Terminated

Automated Myocardial Performance Index Using Samsung HERA W10

Congenital Diaphragmatic Hernia | Neural Tube Defects | Twin to Twin Transfusion Syndrome | Lower Urinary Tract Infection

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

FLT3 Gene Mutation Negative | FLT3 Internal Tandem Duplication Positive | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic...

United States

Clinical Trials on Establish Hematology Reference Intervals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations